A randomized control trial of levofloxacin, terazosin and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006189

Enrollment

Unknown

Registered

2014-10-09

Start date

2015-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type III chronic prostatitis/chronic pelvic pain syndrome

Interventions

1:levofloxacin

2:terazosin

3:combination therapy

Eligibility

Sex/Gender

Male

Age

23 Years to 50 Years

Inclusion criteria

Inclusion criteria: Eligibility requirements included: 1. there are frequent urination, dribbling urine sense and perineum, testicles, lumbosacral pain, discomfort and other symptoms (history longer than 3 months); 2. prostate massage fluid abnormalities; 3. prostate massage fluid bacterial culture negative; 4. no antibiotics and alpha-receptor blocker previous treatment history.

Exclusion criteria

Exclusion criteria: Except for urinary tract infections, benign prostatic hyperplasia, and other pelvic organs diseases.

Design outcomes

Primary

Measure	Time frame
NIH-CPSI;	—

Secondary

Measure	Time frame
EPS-WBC;IIEF-5;	—

Contacts

Public ContactWang Jianxin

wangzijx2009@aliyun.com+86 18769650176

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026